You can help expand this article with text translated from the corresponding article in Swedish. (September 2025) Click [show] for important translation instructions.
|
Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå.[1]
External links
editReferences
edit- ↑ "Annual Report 2021/2022" (PDF). Diamyd Medical AB. Retrieved 20 February 2023.